Results 1 to 10 of about 13,111 (197)

Hepatitis C virus nonstructural protein 5A inhibits thapsigargin-induced apoptosis. [PDF]

PLoS ONE, 2014
BackgroundWe previously reported that the hepatitis C virus (HCV) nonstructural protein 5A (NS5A) down-regulates TLR4 signaling and lipopolysaccharide-induced apoptosis of hepatocytes. There have been several reports regarding the association between HCV
Xia Jiang, Tatsuo Kanda, Shuang Wu, Shingo Nakamoto, Takaji Wakita, Hiroshi Shirasawa, Osamu Yokosuka   +6 more
doaj   +6 more sources

Coordination of Hepatitis C Virus Assembly by Distinct Regulatory Regions in Nonstructural Protein 5A. [PDF]

PLoS Pathogens, 2016
Hepatitis C virus (HCV) nonstructural protein (NS)5A is a RNA-binding protein composed of a N-terminal membrane anchor, a structured domain I (DI) and two intrinsically disordered domains (DII and DIII) interacting with viral and cellular proteins. While
Margarita Zayas, Gang Long, Vanesa Madan, Ralf Bartenschlager   +3 more
doaj   +6 more sources

Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. [PDF]

PLoS Pathogens, 2008
Persistent infection with the hepatitis C virus (HCV) is a major risk factor for the development of liver cirrhosis and hepatocellular carcinoma. With an estimated about 3% of the world population infected with this virus, the lack of a prophylactic ...
Nicole Appel, Margarita Zayas, Sven Miller, Jacomine Krijnse-Locker, Torsten Schaller, Peter Friebe, Stephanie Kallis, Ulrike Engel, Ralf Bartenschlager   +8 more
doaj   +6 more sources

Hepatitis C Virus Nonstructural Protein 5A Inhibits MG132-Induced Apoptosis of Hepatocytes in Line with NF-κB-Nuclear Translocation. [PDF]

PLoS ONE, 2015
BackgroundHepatitis C virus (HCV) infection is one of the major causes of cirrhosis and hepatocellular carcinoma. HCV nonstructural protein 5A (NS5A) is an attractive antiviral target and plays an important role in HCV replication as well as ...
Xia Jiang, Tatsuo Kanda, Shuang Wu, Shingo Nakamoto, Masato Nakamura, Reina Sasaki, Yuki Haga, Takaji Wakita, Hiroshi Shirasawa, Osamu Yokosuka   +9 more
doaj   +3 more sources

Nonstructural protein 5A is incorporated into hepatitis C virus low-density particle through interaction with core protein and microtubules during intracellular transport. [PDF]

PLoS ONE, 2014
Nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) serves dual functions in viral RNA replication and virus assembly. Here, we demonstrate that HCV replication complex along with NS5A and Core protein was transported to the lipid droplet (LD ...
Chao-Kuen Lai, Vikas Saxena, Chung-Hsin Tseng, King-Song Jeng, Michinori Kohara, Michael M C Lai   +5 more
doaj   +3 more sources

Autophagy Induced by the N-Terminus of the Classic Swine Fever Virus Nonstructural Protein 5A Protein Promotes Viral Replication [PDF]

Frontiers in Microbiology, 2021
Although classic swine fever virus (CSFV) infection has been reported to induce autophagy, the specific induced mechanism remains unrevealed. Nonstructural protein 5A (NS5A) of CSFV is a multiphosphorylated protein with multiple functions to regulate ...
Chengcheng Zhang, Xiuling Wang, Jiahao Sun, Mengjiao Guo, Xiaorong Zhang, Yantao Wu   +5 more
doaj   +2 more sources

Hepatitis C virus nonstructural protein 5A perturbs lipid metabolism by modulating AMPK/SREBP-1c signaling [PDF]

Lipids in Health and Disease, 2019
Background Steatosis is an important clinical manifestation associated with chronic hepatitis C virus (HCV) infection. AMP-activated protein kinase (AMPK), a major mediator of lipid metabolism, regulates HCV-associated hepatic steatosis, but the ...
Ziyu Meng, Qiang Liu, Fujun Sun, Ling Qiao   +3 more
doaj   +2 more sources

Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study [PDF]

BMC Gastroenterology, 2020
Background We investigated real-world effectiveness and safety of sofosbuvir and the nonstructural protein 5A inhibitors in the treatment of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, 4, or 6.
Phunchai Charatcharoenwitthaya, Virasak Wongpaitoon, Piyawat Komolmit, Wattana Sukeepaisarnjaroen, Pisit Tangkijvanich, Teerha Piratvisuth, Theeranun Sanpajit, Chinnavat Sutthivana, Chalermrat Bunchorntavakul, Abhasnee Sobhonslidsuk, Soonthorn Chonprasertsuk, Chotipong Siripipattanamongkol, Supatsri Sethasine, Tawesak Tanwandee, The THASL Collaborating Group for the Study of the Use of Direct-acting Antivirals for Chronic Hepatitis C   +14 more
doaj   +2 more sources

Correction: Hepatitis C Virus Nonstructural Protein 5A Inhibits MG132-Induced Apoptosis of Hepatocytes in Line with NF-κB-Nuclear Translocation. [PDF]

PLoS ONE, 2015
PLOS ONE Staff
doaj   +2 more sources

Identification of novel neutralizing determinants for protection against HCV

Hepatology, EarlyView., 2022
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua, Anne F. Pihl, Anna Offersgaard, Rodrigo Velázquez‐Moctezuma, Carlos R. Duarte Hernandez, Elias H. Augestad, Ulrik Fahnøe, Christian K. Mathiesen, Henrik Krarup, Mansun Law, Jannick Prentoe, Jens Bukh, Judith M. Gottwein   +12 more
wiley   +1 more source